Hyperthermic intraperitoneal chemotherapy (HIPEC) did not have an effect on health-related quality of life (HRQOL) in patients with primary ovarian cancer who had undergone cytoreductive surgery. These findings were published in the Journal of Gynecologic Oncology.
This single-blinded, controlled trial randomly assigned patients with stage III-IV epithelial ovarian cancer who had achieved optimal cytoreduction in a 1:1 ratio to undergo cytoreductive surgery with HIPEC (92 patients) or surgery alone (92 patients). HRQOL was evaluated through month 12.
The HIPEC and surgery alone groups, respectively, had a mean age of 53.1±9.7 and 54.0±9.7 years, 65.2% and 55.4% had stage III disease, and 37.0% and 46.7% had received neoadjuvant chemotherapy.
From baseline to month 12, there was no time-by-group interaction in Quality of Life Questionnaire Core 30 (QLQ-C30; P =.5561) or global health status (P =.8233) scores.
Similarly, no differences were reported in abdominal or gastrointestinal symptoms (P =.2867), peripheral neuropathy (P =.7093), other chemotherapy side effects (P =.9882), hormonal symptoms (P =.9513), body image (P =.4639), attitude to disease and treatment (P =.7845), symptom severity (P =.8894), or symptom impact (P =.6498).
A major limitation of this study was that short-term HRQOL was not evaluated.
These data indicated that HIPEC following cytoreductive surgery did not affect HRQOL compared with surgery alone and that HIPEC could be considered a primary treatment option for stage III-IV epithelial ovarian cancer.
Disclosure: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.
Kim JH, Lee D, Lee Y, et al. Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01). J Gynecol Oncol. 2022;33(4):e54. doi:10.3802/jgo.2022.33.e54
This article originally appeared on Oncology Nurse Advisor